Cavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in a Genetic Epilepsy Model

Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer

Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress

Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency

Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

Cavion Announces Promising Phase 2 Data for Essential Tremor in T-CALM Proof-of-Concept Study

Nimbus Therapeutics Names Jeb Keiper as President and Chief Executive Officer

Cavion to Announce Results of its Phase 2 Essential Tremor Clinical Trial

FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency

Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300

Sutro Biopharma Announces $85.0 Million Initial Public Offering

Dr. Jared Gollob Joins Kymera Therapeutics as Chief Medical Officer

Cavion Appoints Julia P. Gregory Executive Chair

Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer

Aeglea Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1-2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency

FDA Grants Orphan Drug Designation to Surface Oncology’s SRF231 for the Treatment of Multiple Myeloma

Sutro Biopharma Collaborates with Merck to Develop Therapeutics for Cancer and Autoimmune Disorders

Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer

Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors

Nimbus Therapeutics Names Adrian Ray, Ph.D., as Senior Vice President of Discovery Biology

Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting

Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930

Nimbus Therapeutics Announces $65 Million in New Financing to Accelerate Pipeline Progress and Expand Discovery Efforts